Lobular Breast Cancer Coalition Marks Awareness Day
News related to:Lobular Breast Cancer Alliance · 2 min read
On October 15, 2026, a coalition of medical professionals and breast cancer advocates gathered to mark Lobular Breast Cancer Awareness Day. The event, held in Toronto, Ontario, highlighted the critical need for greater awareness and research into invasive lobular carcinoma (ILC), the second most common type of breast cancer, which accounts for 15% of all breast cancer diagnoses.
Christine Brezden-Masley, a Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital, and Dr. Sean Egan, a Senior Scientist in the Cell and Systems Biology program at The Hospital for Sick Children and a professor in the Department of Molecular Genetics at the University of Toronto, joined forces with Antonio Cassano, Research Coordinator from the Department of Surgery at Women's College Hospital, and Kimberly Carson, Chief Executive Officer of Breast Cancer Canada. They were joined by Brenda Cunnington, Managing Director, Americas, Trayport at TMX Group, and a Board Director for The Lobular Breast Cancer Alliance (LBCA).
The awareness day was chosen to draw attention to the unique challenges posed by ILC. Unlike other breast cancer types, ILC often does not form a lump and can be difficult to detect on mammograms, especially in women with dense breast tissue. This leads to delayed diagnoses, with tumors often being larger or already metastatic by the time they are detected.
Dr. Brezden-Masley emphasized the importance of early detection and targeted treatments.
Kimberly Carson, CEO of Breast Cancer Canada, echoed the call for increased research funding.
The event concluded with a market closure, symbolizing the collective effort to raise awareness and advocate for better research and treatment options for those affected by ILC. The organizers hope that this day of recognition will lead to more funding and support for ILC research, ultimately improving the lives of patients and their families.
The LBCA, along with its partners, aims to continue advocating for ILC awareness and research. "It's time to talk about lobular cancer," said Dr. Brezden-Masley.
The coalition's efforts are part of a broader movement to address the unique challenges of ILC and ensure that patients receive the care they need. By focusing on early detection and targeted treatments, the group hopes to make significant strides in improving outcomes for those affected by this form of breast cancer.